RT Journal Article
SR Electronic
T1 Systematic evaluation of multifactorial causal associations for Alzheimer’s disease and an interactive platform based on Mendelian randomization analysis——MRAD
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.15.24302839
DO 10.1101/2024.02.15.24302839
A1 Zhao, Tianyu
A1 Li, Hui
A1 Zhang, Meishuang
A1 Xu, Yang
A1 Zhang, Ming
A1 Chen, Li
YR 2024
UL http://medrxiv.org/content/early/2024/07/18/2024.02.15.24302839.abstract
AB Alzheimer’s disease (AD) is a complex degenerative disease of the central nervous system. Traditional epidemiological studies have reported several risk factors for AD. However, most epidemiological studies are insufficient to draw definitive conclusions on causal association due to the potential for reverse causality and confounding bias. Therefore, elucidating its pathogenesis remains challenging. Mendelian randomization (MR) was developed for assessing causality using genetic variants as a new approach in epidemiological research. In this study, we used MR analysis to investigate potential AD risk factors to support extensive AD research. We used the inverse-variance weighted (IVW) model as the major analysis method to perform hypothesis-free Mendelian randomization analysis on the data from MRC IEU OpenGWAS (18,097 exposure traits and 16 AD outcome traits), and conducted sensitivity analysis with six models, to assess the robustness of the IVW results, to identify various classes of risk or protective factors for AD, early-onset AD, and late-onset AD. We generated 400,274 data entries in total, among which the major analysis method of IVW model consists of 73,129 records with 4840 exposure traits, which fall into 10 categories: Disease (n=17,168), Medical laboratory science (n=15,416), Imaging (n=4,896), Anthropometric (n=4,478), Treatment (n=4,546), Molecular trait (n=17,757), Gut microbiota (n=48), Past history (n=668), Family history (n=1,114), and Lifestyle trait (n=7,038). For the convenience of display and operation, an online platform called MRAD has been developed using the Shiny package with MR analysis results. MRAD can be freely accessed online at https://gwasmrad.com/mrad/. Moreover, novel potential AD therapeutic targets (CD33, TBCA, VPS29, GNAI3, PSME1) are identified, among which CD33 was positively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. TBCA and VPS29 were negatively associated with the main outcome traits of AD, as well as with both EOAD and LOAD. GNAI3 and PSME1 were negatively associated with the main outcome traits of AD, as well as with LOAD, but had no significant causal association with EOAD. This is one of the most comprehensive studies in this field. The findings of our research advance understanding of the etiology of AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Natural Science Foundation of China (No. 82302872); the Changchun Science and Technology Planning Project (No. 21ZY18).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:state that source data were openly available before the initiation of the study and they can be located by [MRC IEU OpenGWAS] at (https://gwas.mrcieu.ac.uk/), and [UniProt] at (https://www.uniprot.org/) to all download pages of the original data sourcesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPublicly available datasets were analyzed in this study. These data can be found here: [MRC IEU OpenGWAS] at (https://gwas.mrcieu.ac.uk/), and [UniProt] at (https://www.uniprot.org/), the above database search was completed on January 30, 2023.ADAlzheimer’s diseaseAPPamyloid precursor proteinAβamyloid-βCIconfidence intervalEOADearly-onset Alzheimer’s diseaseeQTLexpression Quantitative Trait LociG proteinguanine nucleotide-binding protein G(k) subunit alphaGDPguanosine diphosphateGlnglutamineGTPguanosine triphosphateGWASgenome-wide association studyHLAhuman leukocyte antigenIVWInverse Variance WeightedLDlinkage disequilibriumLDLlow density lipoproteinLOADlate-onset Alzheimer’s diseaseMRMendelian randomizationMRADMendelian randomization for Alzheimer’s diseaseORodds ratioPSME1proteasome activator complex subunit 1RCTrandomized controlled trialSIGLECSsialic acid-binding immunoglobulin like lectinsSNPsSingle nucleotide polymorphismsSNXsSorting NexinsTBCAtubulin-specific chaperone ATBCstubulin-specific chaperonesVLDLvery low density lipoproteinVPS29vacuolar protein sorting-associated protein 29WHOWorld Health Organization